JP2022513798A5 - - Google Patents
Info
- Publication number
- JP2022513798A5 JP2022513798A5 JP2021533535A JP2021533535A JP2022513798A5 JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5 JP 2021533535 A JP2021533535 A JP 2021533535A JP 2021533535 A JP2021533535 A JP 2021533535A JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- composition according
- peptide
- item
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024214382A JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779885P | 2018-12-14 | 2018-12-14 | |
| US62/779,885 | 2018-12-14 | ||
| US201962836520P | 2019-04-19 | 2019-04-19 | |
| US62/836,520 | 2019-04-19 | ||
| PCT/US2019/066376 WO2020124032A1 (en) | 2018-12-14 | 2019-12-13 | Transferrin receptor targeting peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214382A Division JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513798A JP2022513798A (ja) | 2022-02-09 |
| JP2022513798A5 true JP2022513798A5 (cg-RX-API-DMAC7.html) | 2022-12-20 |
| JP7664158B2 JP7664158B2 (ja) | 2025-04-17 |
Family
ID=71077078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533535A Active JP7664158B2 (ja) | 2018-12-14 | 2019-12-13 | トランスフェリン受容体標的ペプチド |
| JP2024214382A Pending JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214382A Pending JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220048961A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3893913B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7664158B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113329758A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019398467A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120466A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283839A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020124032A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| JP7231745B2 (ja) | 2020-06-22 | 2023-03-01 | 中国科学院昆明▲動▼物研究所 | 抗SARS-CoV-2薬の調製における干渉ポリペプチドの応用 |
| CN111647048B (zh) * | 2020-06-22 | 2021-04-02 | 中国科学院昆明动物研究所 | 干扰多肽在制备抗SARS-CoV-2药物中的应用 |
| JP2022014707A (ja) * | 2020-07-07 | 2022-01-20 | 東亞合成株式会社 | キャリアペプチドフラグメントおよびその利用 |
| EP4188422A4 (en) * | 2020-07-30 | 2024-08-28 | University of Washington | Transferrin receptor binding proteins |
| US20250195673A1 (en) * | 2020-11-30 | 2025-06-19 | Fred Hutchinson Cancer Center | Compositions and methods for selective depletion of target molecules |
| EP4298132A4 (en) * | 2021-02-23 | 2025-03-12 | Ichilov Tech Ltd. | FUSION PROTEINS FOR THE TREATMENT OF CNS DISEASES |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2023023031A2 (en) * | 2021-08-17 | 2023-02-23 | Blaze Bioscience, Inc. | Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof |
| JPWO2023022234A1 (cg-RX-API-DMAC7.html) * | 2021-08-19 | 2023-02-23 | ||
| KR102934033B1 (ko) * | 2021-10-01 | 2026-03-06 | 서울대학교산학협력단 | 혈액 뇌장벽 투과용 펩타이드 및 이의 용도 |
| CN118139896A (zh) * | 2021-10-15 | 2024-06-04 | 南通壹宸生物医药科技有限公司 | 一种双特异性结合分子 |
| CN115160408B (zh) * | 2022-06-29 | 2025-04-22 | 辽宁天增祥生物科技有限公司 | 降压肽或中国蛤蜊降压肽提取物及其应用 |
| CN115925981B (zh) * | 2022-08-18 | 2025-05-23 | 河南工业大学 | 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用 |
| TWI877887B (zh) * | 2022-11-29 | 2025-03-21 | 法信諾生醫股份有限公司 | 轉運胜肽及其應用 |
| TW202434613A (zh) * | 2023-02-17 | 2024-09-01 | 日商肽夢想股份有限公司 | 人類運鐵蛋白受體結合肽 |
| KR20260021596A (ko) | 2023-04-05 | 2026-02-13 | 아이오니스 파마수티컬즈, 인코포레이티드 | Pln 발현을 감소시키는 화합물 및 방법 |
| WO2024238304A2 (en) * | 2023-05-12 | 2024-11-21 | University Of Washington | Improved transferrin receptor binding proteins |
| AU2024329222A1 (en) * | 2023-08-18 | 2026-02-12 | Eli Lilly And Company | Engineered transferrin receptor binding peptides as well as methods of making and using the same |
| CN119896743B (zh) * | 2023-10-26 | 2025-09-26 | 华南理工大学 | 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用 |
| WO2025090121A1 (en) * | 2023-10-27 | 2025-05-01 | Yale University | Conjugate and methods of treatment |
| WO2025096245A1 (en) * | 2023-11-02 | 2025-05-08 | The Regents Of The University Of California | Design rules for endosomal escape |
| CN120647772A (zh) * | 2024-03-15 | 2025-09-16 | 迦进生物医药(上海)有限公司 | 特异性结合转铁蛋白受体的多肽及其应用 |
| CN120459270B (zh) * | 2025-05-16 | 2026-06-09 | 中国人民解放军海军军医大学 | OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002236499A1 (en) * | 2000-11-30 | 2002-06-11 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| US20040157330A1 (en) * | 2003-01-09 | 2004-08-12 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
| US7973019B1 (en) * | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| WO2013123457A1 (en) * | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| WO2013177062A2 (en) * | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| CN103897033A (zh) * | 2014-03-31 | 2014-07-02 | 中国药科大学 | 转铁蛋白受体TfR特异性结合肽及其应用 |
| CA2967830A1 (en) * | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | Tfr selective binding compounds and related methods |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| CA3033082A1 (en) * | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
-
2019
- 2019-12-13 AU AU2019398467A patent/AU2019398467A1/en not_active Abandoned
- 2019-12-13 EP EP19897452.9A patent/EP3893913B1/en active Active
- 2019-12-13 WO PCT/US2019/066376 patent/WO2020124032A1/en not_active Ceased
- 2019-12-13 US US17/312,703 patent/US20220048961A1/en active Pending
- 2019-12-13 CA CA3120466A patent/CA3120466A1/en active Pending
- 2019-12-13 JP JP2021533535A patent/JP7664158B2/ja active Active
- 2019-12-13 CN CN201980089966.8A patent/CN113329758A/zh active Pending
-
2021
- 2021-06-09 IL IL283839A patent/IL283839A/en unknown
-
2024
- 2024-12-09 JP JP2024214382A patent/JP2025038018A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dal Corso et al. | A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo | |
| Thomas et al. | Antibody–drug conjugates for cancer therapy | |
| Nasiri et al. | Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy | |
| US10588938B2 (en) | Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway | |
| ES2938186T3 (es) | Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco | |
| Lancman et al. | Bispecifics, trispecifics, and other novel immune treatments in myeloma | |
| JP2023101813A (ja) | 抗folr1免疫複合体を含む治療組み合わせ | |
| EP2233156B1 (en) | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates | |
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| BR112015022585B1 (pt) | Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos | |
| ES2872534T3 (es) | Métodos para revertir la caquexia y prolongar la supervivencia que comprenden administrar un modulador de GDF15 y un agente anticanceroso | |
| JP2021102648A (ja) | 抗folr1免疫複合体投与計画 | |
| ES2875365T3 (es) | Conjugados de fármaco de anticuerpos MET | |
| CA2748291A1 (en) | Cancer treatment | |
| JP2019524713A5 (cg-RX-API-DMAC7.html) | ||
| CN108602890A (zh) | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 | |
| JP2020517658A5 (cg-RX-API-DMAC7.html) | ||
| JP7608336B2 (ja) | 中枢神経系原発リンパ腫の併用治療 | |
| JP2024542021A (ja) | ペイロードのin vivo標的化送達用のテトラジンコンジュゲート | |
| JP2020527556A5 (cg-RX-API-DMAC7.html) | ||
| Wu | Enhancement of immunotoxin activity using chemical and biological reagents | |
| WO2023081809A1 (en) | Trans-cyclooctene-modified bispecific antibodies | |
| JP6782932B2 (ja) | Npr−aアゴニストの新規用途 | |
| EP4472741A1 (en) | Combination therapy comprising anti-ccr9 antibody and vincristine for cancer | |
| Koli et al. | Lung cancer receptors and targeting strategies |